Gastric cancer
Conditions
Interventions
Sponsors
Division of Biological Regulation and Oncology, Department of Surgery, Graduate School of Medicine, Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Selection Criteria 1)Pathologically confirmed gastric cancer 2) i)cStageIIIa or IIIb ii)Borrmann Type III with the maximum tumor diameter of 8cm or more iii)Borrmann Type IV 3) a case with clinically resectable legion 4) a case with target lesion or measurable lesion 5) No previous treatment 6) Age between 20 and 75 years old when an informed concent was taken. 7) ECOG 0 or 1 Informed concent 8)Biology and biochemistry data are fit for the following criteria within 14 days before registration. a) WBC ≥ 3,500/µL b) PLT ≥ 100,000/µL c) Hb ≥ 9.0 g/dL d) AST, ALT ≤ ULN x 2.0 e) T-Bil ≤ ULN x 2.0 f) CRE ≤ ULN or CCR ≥ 50ml/min 9) Patient who can eat orally and is judged to be appropriate for neoadjuvant chemotherapy by the principal investigator 10) written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1)Fresh bleeding from the tumor 2)Paralysis of intestine or ileus 3)Diarrhea(watery stool) 4) Synchronous multicancer 5) infection 6) Interstitial pneumonitis or fibroid lung 7) a large amount of pleural effusion or ascites 8) Jaundice 9)Uncontrollable diabetes mellitus, 10) heart failure requiring the treatment, myocardial infarction within 6 months, uncontrolled arrhythmia or angina 11)Patients pregnant or in lactation, or wish to become pregnant during this study. Male patients who intend to make someone pregnant during this study 12)Patient who has experienced serious drug allergy in the past 13)Patient who is judged to be inappropriate for this study by the principal investigator or the doctors in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate, pathological response | — |
Secondary
| Measure | Time frame |
|---|---|
| Over all survival , relapse free survival, curative resection rate, operative complication rate, adverse event | — |
Countries
Japan
Contacts
Public ContactMakoto Kinouchi
Graduate School of Medicine, Tohoku University Division of Biological Regulation and Oncology, Department of Surgery
Outcome results
None listed